OBJECTIVES/HYPOTHESIS: Routine surveillance is advocated to detect recurrent disease after treatment for laryngeal cancer. This aim of this study was to determine the 1- and 5-year postrecurrence mortality for laryngeal cancers and evaluate whether more intensive surveillance improved survival. STUDY DESIGN: Retrospective cohort study. METHODS: Patients with recurrent cancers (1992-1999) were identified in a national cancer clinical database. Multivariate analysis was used to evaluate the effect of surveillance on postrecurrence survival. RESULTS: Of 2,121 recurrent cancers identified, 913 were laryngeal. Patients with laryngeal cancer recurrence had 27% (P = .001) and 22% (P = .007) better odds of 1- and 5-year survival than other sites. The 1- and 5-year postrecurrence survival rates for laryngeal cancer patients were 72.4% and 41.3%, respectively. Glottic cancer cases had the best postrecurrence life expectancy. Multivariate regression revealed that clinical surveillance intensity had no independent impact on their survival (P < .05). However, patients with recurrent glottic cancer seen in surveillance had 23% improved odds of survival (P = .037). CONCLUSIONS: More frequent surveillance visits was not associated with a survival advantage in the overall population. Patients with glottic cancer had a postrecurrence survival advantage if seen during the surveillance period. Laryngeal cancer patients had better postrecurrence survival than other head and neck sites.
OBJECTIVES/HYPOTHESIS: Routine surveillance is advocated to detect recurrent disease after treatment for laryngeal cancer. This aim of this study was to determine the 1- and 5-year postrecurrence mortality for laryngeal cancers and evaluate whether more intensive surveillance improved survival. STUDY DESIGN: Retrospective cohort study. METHODS:Patients with recurrent cancers (1992-1999) were identified in a national cancer clinical database. Multivariate analysis was used to evaluate the effect of surveillance on postrecurrence survival. RESULTS: Of 2,121 recurrent cancers identified, 913 were laryngeal. Patients with laryngeal cancer recurrence had 27% (P = .001) and 22% (P = .007) better odds of 1- and 5-year survival than other sites. The 1- and 5-year postrecurrence survival rates for laryngeal cancerpatients were 72.4% and 41.3%, respectively. Glottic cancer cases had the best postrecurrence life expectancy. Multivariate regression revealed that clinical surveillance intensity had no independent impact on their survival (P < .05). However, patients with recurrent glottic cancer seen in surveillance had 23% improved odds of survival (P = .037). CONCLUSIONS: More frequent surveillance visits was not associated with a survival advantage in the overall population. Patients with glottic cancer had a postrecurrence survival advantage if seen during the surveillance period. Laryngeal cancerpatients had better postrecurrence survival than other head and neck sites.
Authors: A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken Journal: AJNR Am J Neuroradiol Date: 2020-06-18 Impact factor: 3.825
Authors: Haley K Perlow; Stephen J Ramey; Vincent Cassidy; Deukwoo Kwon; Benjamin Farnia; Elizabeth Nicolli; Michael A Samuels; Laura Freedman; Nagy Elsayyad; Raphael Yechieli; Stuart E Samuels Journal: Laryngoscope Date: 2018-12-24 Impact factor: 3.325
Authors: Joan L Warren; Angela Mariotto; Danielle Melbert; Deborah Schrag; Paul Doria-Rose; David Penson; K Robin Yabroff Journal: Med Care Date: 2016-08 Impact factor: 2.983
Authors: Petr Szturz; Carl Van Laer; Christian Simon; Dirk Van Gestel; Jean Bourhis; Jan B Vermorken Journal: Front Oncol Date: 2020-05-06 Impact factor: 6.244